Close Menu

Precision Oncology Business, Policy & Funding

Breaking news on Precision Oncology business, policy & funding.

The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. 

The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.

The UK-based firm will use the funds to advance its bespoke neoantigen-targeting T-cell therapies for solid cancers including melanoma and NSCLC.

Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.

The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.